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Abstract
The TRPV1 ion channel is expressed in nociceptors, where pharmacological modulation of its function may oﬀer a
means of alleviating pain and neurogenic inﬂammation processes in the human body. The aim of this study was to
investigate the eﬀects of cholesterol depletion of the cell on ion-permeability of the TRPV1 ion channel. The
ion-permeability properties of TRPV1 were assessed using whole-cell patch-clamp and YO-PRO uptake rate studies on
a Chinese hamster ovary (CHO) cell line expressing this ion channel. Prolonged capsaicin-induced activation of TRPV1
with N-methyl-D-glucamine (NMDG) as the sole extracellular cation, generated a biphasic current which included an
initial outward current followed by an inward current. Similarly, prolonged proton-activation (pH 5.5) of TRPV1 under
hypocalcemic conditions also generated a biphasic current including a fast initial current peak followed by a larger
second one. Patch-clamp recordings of reversal potentials of TRPV1 revealed an increase of the ion-permeability for
NMDG during prolonged activation of this ion channel under hypocalcemic conditions. Our ﬁndings show that
cholesterol depletion inhibited both the second current, and the increase in ion-permeability of the TRPV1 channel,
resulting from sustained agonist-activation with capsaicin and protons (pH 5.5). These results were conﬁrmed with
YO-PRO uptake rate studies using laser scanning confocal microscopy, where cholesterol depletion was found to
decrease TRPV1 mediated uptake rates of YO-PRO. Hence, these results propose a novel mechanism by which cellular
cholesterol depletion modulates the function of TRPV1, which may constitute a novel approach for treatment of
neurogenic pain.
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Background
Nociceptors are sensory neurons which respond to
noxious stimuli, resulting in the perception of pain. Noci-
ceptors are also involved in neurogenic inﬂammation,
i.e. inﬂammatory symptoms that result from the release
of pro-inﬂammatory substances (e.g. the neuropeptide
substance P) from these sensory nerve terminals [1,2].
A key mediator of nociception and neurogenic inﬂam-
mation is the TRPV1 ion channel which is expressed in
nociceptors [3-5]. TRPV1 is activated by a broad range
of chemical stimuli which includes protons, capsaicin,
and arachnoid toxin, but also environmental eﬀects such
as painfully hot temperatures (>42◦C). TRPV1 mediates
an excitatory response to stimuli, i.e. it is a nonselective
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cation channel that is permeable not only for monovalent
cations, but also for Ca2+ and relatively large cations
[3,4,6-9]. TRPV1 has been shown to possess a dynamic
selectivity for ions during stimulation similar to what
has been observed for P2X purinoceptor channels, and
later also for the TRPA1 ion channel, i.e. a time- and
agonist concentration-dependent increase of the relative
permeability of the ion channel to large cations [10-14].
Thus, these physicochemical properties of TRPV1 may
contribute to its capability of mediating nociception and
neurogenic inﬂammation.
Neurogenic inﬂammation is generated through exces-
sive stimulation of the nociceptor terminals within injured
or inﬂamed tissue. As indicated above, the nocicep-
tors are sensitized in this process by the release of
pro-inﬂammatory substances or inﬂammatory mediators.
However, attempts to decrease sensitization of nocicep-
tors, and thereby symptoms of neurogenic inﬂammation
© 2013 Jansson et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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(especially the enhanced pain perception), by using antag-
onists to pro-inﬂammatory substances have not been
successful, since these mediators are involved in similar
actions, or functions [2]. TRPV1 signiﬁcantly contributes
to the integration of these actions of various inﬂammatory
modulators, which makes this ion channel a central regu-
lator of nociceptor excitability. Consequently, the key role
of TRPV1 in the onset and maintenance of neurogenic
inﬂammation, has identiﬁed it as a potential drug target
for alleviating inﬂammatory pain [15-17].
Pharmacological perturbation of cholesterol synthesis,
interfering with ion channel function, may represent a
novel therapeutic approach to inhibit TRPV1-mediated
responses and sensitization of nociceptors in the process
of neurogenic inﬂammation. Interestingly, recent stud-
ies suggest that cholesterol interferes with the function
of TRPV1 [18-20], but none of them demonstrate how
cholesterol modulation aﬀects the ion-permeability prop-
erties of this channel, which we believe may contribute
to drastic changes in the sensitization of nociceptors. By
using whole-cell patch-clamp recording and laser scan-
ning confocal microscopy (LSCM) studies of uptake rates
of the ﬂuorescent dye YO-PRO [10,12], we have here
investigated the eﬀects of cellular cholesterol depletion
on the dynamic permeability properties of the TRPV1
ion channel. We found that cholesterol depletion impairs
the ability of TRPV1 to N-methyl-D-glucamine (NMDG)
during hypocalcemic conditions, upon sustained activa-
tion with capsaicin and to decrease secondary currents
upon sustained activation with protons. We also found
cholesterol depletion to decrease the cellular uptake rate
of YO-PRO via TRPV1, when activated with capsaicin or
protons. Thus, our ﬁndings suggest that cholesterol deple-
tion modulates the extent of TRPV1 pore dilation under
hypocalcemic conditions.
Results
For electrophysiological experiments and ﬂuorescence
studies, a Chinese hamster ovary (CHO) cell line,
expressing human TRPV1 channels was used. Methyl-
β-cyclodextrin (MβCD) alone, or in combination with
cholesterol dissolved in serum-free culturing mediumwas
used to perturbate the cholesterol content of the CHO
cells [18,21,22].
Decrease of cholesterol content in CHO cells
The cholesterol content of CHO cells was quantitated
with gas chromatography–mass spectrometry (GC–MS)
[23-26], and found to be decreased by both 15 min treat-
ment with 10 mM MβCD or 90 min treatment with
2.5 mM MβCD:cholesterol (10:1). Cells treated with 10
mM MβCD had a cholesterol content of 2.55 ± 0.58
μg/million cells (n = 9), MβCD:cholesterol-treated cells
had a cholesterol content of 1.82 ± 0.22 μg/million cells
(n = 8), compared to control cells which had a choles-
terol content of 4.0 ± 1.4 μg/million cells (n = 9), i.e. the
cholesterol content of the cells was decreased by ∼36%
(p < 0.05) and ∼54% (p < 0.001) using the MβCD or the
MβCD:cholesterol treatment, respectively.
Cholesterol depletion aﬀects NMDG-permeability of TRPV1
in CHO cells
To assess the eﬀect of cholesterol on the pore dilation
of TRPV1, voltage ramps were measured during 1 min
application of 1 μMcapsaicin, in extracellular buﬀers with
either sodium ions, or NMDG as the sole cation (buﬀer 1
or 2, respectively), combined with an intracellular buﬀer
mainly containing sodium ions (buﬀer 3). NMDG is an
amino sugar which becomes cationic at neutral pH.
No eﬀect on the shift of reversal potential Erev
was observed for 90 min treatment with 2.5 mM
MβCD:cholesterol (10:1) in the extracellular sodium
ion-containing buﬀer (Figure 1A–C). Here, in MβCD:
cholesterol-treated cells, Erev shifted from −11.7±
4.1 mV to −24.9 ± 5.8 mV (n = 6), whereas for con-
trol cells, Erev shifted from −10.35 ± 0.68 mV to −19.6 ±
9.0 mV (n = 4). However, with the extracellular buﬀer
containing NMDG, a signiﬁcant eﬀect by treatment with
MβCD:cholesterol on the ﬁnal reversal potentials was
observed. ForMβCD:cholesterol-treated cells, Erev shifted
from −77.7± 2.5 mV to −66.7± 7.6 mV (n = 4), whereas
for control cells, Erev shifted from−83±10mV to−43±14
mV (n = 4, p < 0.05, Figure 1D–F). Using eq. 1 (see
Methods), the relative permeability PNMDG/PNa after 20
s of capsaicin application was calculated to be on average
0.12 and 0.46 for MβCD:cholesterol-treated cells and con-
trol cells, respectively, i.e. a decrease of cellular cholesterol
content resulted in a decrease of PNMDG/PNa in TRPV1
by ∼70%.
Cholesterol depletion aﬀects the capsaicin-activated
current mediated by TRPV1 in CHO cells
Whole-cell patch-clamp traces for TRPV1 during appli-
cation of 1 μM capsaicin from voltage ramp experiments
were evaluated at a membrane potential of −60 mV, with
extracellular NMDG (buﬀer 2), and intracellular sodium
ions (buﬀer 3). Whereas TRPV1 initially mediated an out-
ward current which upon sustained activation changed
into an inward current for control cells, the current in
cells treated for 90 min with 2.5 mM MβCD:cholesterol
(10:1) remained directed outward (Figure 2A). In the
MβCD:cholesterol-treated cells, the initial current den-
sity induced by capsaicin was 23 ± 18 pA/pF and reduced
to 5.2 ± 2.9 pA/pF (n = 4), remaining outwardly
directed, whereas in control cells, the initial current den-
sity changed from 22 ± 10 pA/pF to −19 ± 14 pA/pF
(n = 4). There was no diﬀerence between the initial cur-
rent densities upon activation with agonist, but the late
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Figure 1 Eﬀect of cholesterol depletion for 90min treatment with 2.5 mMMβCD:cholesterol (10:1) on NMDG-permeability of
capsaicin-activated TRPV1. The relative permeability of NMDG with respect to sodium ions in TRPV1 was assessed with whole-cell patch-clamp
recording by measuring reversal potentials with voltage ramps ranging from −120 mV to+30 mV over 150 ms, upon sustained activation with 1
μM capsaicin. Lower-case letters in panels with representative current-voltage (IV) relations indicate timepoints during the stimulation protocol: (a)
before application of capsaicin; (b) ﬁrst time-point of capsaicin application; (c) late time-point before capsaicin removal; (d) after removal of
capsaicin. Panels (A–C) show data from experiments using extracellular sodium ions (extracellular buﬀer 1, intracellular buﬀer 3). Panels (D–F) show
data from experiments using extracellular NMDG (extracellular buﬀer 2, intracellular buﬀer 3). (A) Representative IV-traces of a control cell. (B)
Representative IV-traces of a cell treated with MβCD:cholesterol. (C) Reversal potentials for TRPV1 with extracellular sodium ions during application
of capsaicin, no diﬀerence of reversal potential was observed between the groups (n = 4–6). (D) Representative IV-traces of a control cell. (E)
Representative IV-traces of a cell treated with MβCD:cholesterol. (F) Reversal potentials for TRPV1 with extracellular NMDG during application of
capsaicin. The reversal potential shift observed in control cells was inhibited by treatment with MβCD:cholesterol (n = 4, p < 0.05).
phase current densities were diﬀerent (p < 0.05). Cur-
rent densities were integrated over the time of application
of capsaicin, and showed the net ﬂow of ions to be out-
ward (0.66 ± 0.28 nA·s/pF, n = 4) and inward (−0.65 ±
0.50 nA·s/pF, n = 4), for MβCD:cholesterol-treated and
control cells, respectively (p < 0.005).
For cells that were treated for 15 min with 10 mM
MβCD, uptake of YO-PRO was observed with LSCM dur-
ing activation of TRPV1 with 1 μM capsaicin in presence
of 1 μMYO-PRO in extracellular buﬀer 8 (Figure 2B). The
ﬂuorescence uptake rate increased during the initial 20 s
of stimulation with 1 μMcapsaicin in bothMβCD-treated
cells and control cells. However, after∼20 s of stimulation
the ﬂuorescence uptake rate in MβCD-treated cells was
3.8 ± 2.0 A.U./s (n = 41) compared to control cells with
a rate of 8.1 ± 2.6 A.U./s (n = 34). Hence, the MβCD-
treatment resulted in a reduction by ∼50% of the uptake
rate (p < 0.001).
Cholesterol depletion aﬀects the proton-activated current
mediated by TRPV1 in CHO cells
Whole-cell patch-clamp recordings of control cells at −60
mV with extracellular buﬀer 4 (pH 5.5), and intracellular
buﬀer 5 (Figure 3A), showed an initial response fol-
lowed by desensitization. A second, larger current was
also observed which desensitized until it reached a
steady-state level. In cells treated for 90 min with 2.5
mM MβCD:cholesterol (10:1), identical initial current
responses were observed. However, the magnitude of the
second current was smaller. The initial current density I1
upon activation was −0.42 ± 0.30 nA/pF for treated cells
and −0.46± 0.15 nA/pF for control cells. Hence, this cur-
rent was unaﬀected by treatment with MβCD:cholesterol.
The second current density I2, was −0.46 ± 0.44 nA/pF
for treated cells (n = 6) and −1.20 ± 0.53 nA/pF for con-
trol cells (n = 6). Thus, this current density was found to
be ∼60% smaller for cells treated with MβCD:cholesterol
compared with control cells (p < 0.05, Figure 3B).
For cells that were treated for 15 min with 10 mM
MβCD, uptake of YO-PRO was observed with LSCM dur-
ing activation of TRPV1 with pH 5.5 (extracellular buﬀer
4) in the presence of 1 μM YO-PRO, using a microﬂu-
idic pipette for drug delivery [27,28]. The uptake rate
increased during the initial 10 s of stimulation with pH
5.5 where it reached a maximum for both treated and
control cells, but no signiﬁcant diﬀerence in uptake rate
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Figure 2 Eﬀect of cholesterol depletion for 15 min treatment
with 10mMMβCD and for 90min treatment with 2.5 mM
MβCD:cholesterol (10:1) on capsaicin-activated TRPV1.
(A) Whole-cell patch-clamp recordings for TRPV1 treated with
MβCD:cholesterol during application with 1 μM capsaicin from ramp
experiments evaluated at a holding potential of −60 mV, with
extracellular NMDG (buﬀer 2), and intracellular sodium ions (buﬀer 3).
Current densities were initially equal for both the control and treated
cells, but the time-dependent switch of ion ﬂow direction observed
in control cells was inhibited by treatment with MβCD:cholesterol
(n = 4 , p < 0.05). (B) YO-PRO uptake was observed during
stimulation of MβCD-treated cells with 1 μM capsaicin (extracellular
buﬀer 8). The ﬂuorescence uptake rate increased during activation
with 1 μM capsaicin, and a signiﬁcant diﬀerence in rate was observed,
as the uptake rate after ∼20 s of stimulation was reduced by∼ 50% in
treated cells compared to control cells (n = 34–41, p < 0.001).
compared to control cells was observed. The uptake rate
was 2.09± 0.86 A.U./s (n = 46) and 2.3± 1.0 A.U./s (n =
34) for treated and control cells, respectively (Figure 3C).
In cells treated for 90 min with 2.5 mM MβCD:
cholesterol (10:1), a change in uptake rate of YO-PRO
could also be observed during activation of TRPV1 with
pH 5.5 (extracellular buﬀer 4) in the presence of 1 μM
YO-PRO, using the microﬂuidic device for rapid well per-
fusion. However, here the uptake rate was ∼70% less than
the rate observed in control cells (Figure 3D), as the uptake
rate after ∼30 s of activation with pH 5.5 was 0.55 ± 0.45
A.U./s (n = 30) in cells treated with MβCD:cholesterol
compared to an uptake rate of 1.87± 0.91 A.U./s (n = 15)
in control cells (p < 0.001).
No eﬀect of cholesterol depletion on heat-activated
current mediated by TRPV1 in CHO cells
Uptake of YO-PRO was measured with LSCM dur-
ing sustained activation of TRPV1 with heat (45◦C), in
cells under hypocalcemic conditions (extracellular buﬀer
8) and in presence of 1 μM YO-PRO. No increase of
the uptake rate of YO-PRO during heat-activation was
observed in control cells (n = 94). Also, there was no
diﬀerence of uptake rates between cells treated for 90
min with 2.5 mM MβCD:cholesterol (10:1) (n = 80)
and control cells (Figure 4A). Further, whole-cell patch-
clamp recordings of TRPV1-mediated currents in CHO
cells generated by heat, where temperature was ramped
from room temperature (∼20◦C) to 38◦C, then stepped
upwards by 1◦C to 49◦C, held at 10 s per step, at −60
mV in the presence of extra- and intracellular calcium
(buﬀers 6 and 7, respectively), showed that these current
responses were unaﬀected by treatment of the cells for
90 min with 2.5 mM MβCD:cholesterol (10:1). At each
temperature, the amplitudes of the steady-state current
densities in cells treated with MβCD:cholesterol (n = 9)
were similar to those of control cells (n = 5, Figure 4B–C).
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Figure 3 Eﬀect of cholesterol depletion for 90 min treatment with 2.5 mMMβCD:cholesterol (10:1) but not for 15min treatment with 10
mMMβCD on proton-activated TRPV1. (A) Representative traces of TRPV1 whole-cell response of cells treated with MβCD:cholesterol, activated
with pH 5.5, clamped at −60 mV (extracellular buﬀer 4, intracellular buﬀer 5), containing two currents, I1 and I2. (B) The initial current density upon
activation I1 was unaﬀected by treatment with MβCD:cholesterol whereas the following current density I2 was 60% lower for cells treated with
MβCD:cholesterol compared to control cells (n = 6, p < 0.05). (C) YO-PRO uptake was observed during stimulation with pH 5.5 (extracellular buﬀer
4) in cells treated with MβCD. Fluorescence uptake rate increased during activation with pH 5.5, but no signiﬁcant diﬀerence in rate could be
determined from the treatment (n = 34–46). (D) YO-PRO uptake was observed during stimulation with pH 5.5 (extracellular buﬀer 4) in cells treated
for 90 min with 2.5 mMMβCD:cholesterol (10:1). Fluorescence uptake rate increased during activation with pH 5.5, the MβCD:cholesterol-treatment
resulted in a reduction by∼70% of the uptake rate in treated cells compared to control cells (n = 15–30, p < 0.001) after ∼30 s of stimulation.
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Figure 4 No eﬀect of cholesterol depletion for 90 min treatment with 2.5 mMMβCD:cholesterol (10:1) on heat-activated TRPV1 currents.
(A) The uptake rate of YO-PROmediated by TRPV1 during sustained activation with heat (45◦C) of cells in extracellular buﬀer 8, was unaﬀected by
treatment with MβCD:cholesterol (n = 80–94). (B) Representative trace of a TRPV1 whole-cell response (bottom) from a cell clamped at −60 mV
(extracellular buﬀer 6, intracellular buﬀer 7), elicited by a heat-protocol (top) where temperature was ramped from room temperature (∼20◦C) to
38◦C, then stepped upwards by 1◦C to 49◦C, held at 10 s per step. (C) Heat-activated TRPV1 current densities were unaﬀected by treatment with
MβCD:cholesterol (n = 5–9).
Discussion
In accordance with a previous study by Caterina and co-
workers [12], our data demonstrates that, under hypocal-
cemic conditions, prolonged agonist-induced activation of
the TRPV1 channel leads to a time-dependent increase of
permeability of the channel to large cations. It has been
proposed that conformational changes, and not only a
rigid pore enlargement, may contribute to the dynamic
ionic selectivity of the channel [12]. The major ﬁnding of
our study is that a decrease of the cholesterol content by
∼54% in the cell inhibits the time-dependent increase of
the permeability of the large cation NMDG in the TRPV1
channel under hypocalcemic conditions.
Treatment of cells with 10 mM MβCD and 2.5 mM
MβCD:cholesterol (10:1) was quantitated with GC–MS,
showing a decrease in cholesterol content for the treated
cells by ∼36% and ∼54%, respectively. For cells treated
with MβCD:cholesterol, the reversal potential changed
with extracellular NMDG during activation of TRPV1
with 1 μM capsaicin, whereas the reversal potential for
extracellular sodium ions was unaﬀected (Figure 1). The
relative permeability of NMDG with respect to sodium
ions was decreased by ∼70%, due to reduction of the
amount of cholesterol in the cell. In measurements with
extracellular NMDG the currents were initially directed
outward upon activation with 1 μM capsaicin, which can
be explained by NMDG being too large to pass through
the ion channel. Upon sustained activation with 1 μMcap-
saicin under hypocalcemic conditions, the pore of TRPV1
expands, eventually allowing for entry of NMDG, result-
ing in an inward current. This expansion of the pore was
inhibited through treatment with MβCD:cholesterol, as
the change-of-sign of TRPV1-mediated current observed
in control cells was made absent by cholesterol depletion
(Figure 2A). The net ﬂow of ions through TRPV1 into the
cell during the time of application of capsaicin was found
to be outward and inward for MβCD:cholesterol-treated
and control cells, respectively. When TRPV1 was acti-
vated with pH 5.5 in cells treated with MβCD:cholesterol,
the larger second current densities, arising during sus-
tained activation, were found to be decreased by ∼60%
(Figure 3A–B).
As an independent assay for probing TRPV1 pore dila-
tion, YO-PRO uptake during stimulation with 1 μM cap-
saicin or pH 5.5 was measured with LSCM [12,27] on cells
treated with 10 mMMβCD or 2.5 mMMβCD:cholesterol
(10:1). Whereas a milder cholesterol depletion by ∼36%,
using 10 mM MβCD, was unable to aﬀect the uptake
rate of YO-PRO when activating TRPV1 with pH 5.5
(Figure 3C), it was found to decrease the uptake rate by
∼50% when TRPV1 was activated with 1 μM capsaicin
(Figure 2B). However, a cholesterol depletion of ∼54%,
using 2.5 mM MβCD:cholesterol (10:1), was shown to
decrease the uptake rate by ∼70% when TRPV1 was acti-
vated with pH 5.5 (Figure 3D). This data suggests that
there exists a required level of cholesterol depletion for
the inhibition of TRPV1 pore dilation, which varies with
type of agonist. Also, these results further support the
eﬀect of cholesterol depletion on TRPV1 permeability
properties observed with patch-clamp recordings, dur-
ing sustained application of agonist under hypocalcemic
conditions.
Our results diﬀer compared to a previous study which
demonstrates that cholesterol depletion with a removal
of 95% of endogenous cholesterol results in a decreased
amount of the TRPV1 protein in the cell membrane, sug-
gesting that this protein might be localized in cholesterol-
rich microdomains or lipid rafts in nociceptors [18]. In
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our experiments, the cholesterol content was decreased to
a lesser extent, which seems to change the permeability
properties of TRPV1, but not the amount of TRPV1 pro-
tein in the cell membrane. If activated with heat, or in the
presence of extracellular calcium, permeability changes
are not induced upon sustained activation in TRPV1 [12].
Here, as a control, depletion of cholesterol had no eﬀect
on the uptake rate of YO-PRO under hypocalcemic con-
ditions, or on the current response in the presence of
calcium, mediated by heat-activated TRPV1 (Figure 4).
This is in agreement with a previous study where choles-
terol depletion was shown to neither have any eﬀect on
activation, nor on sensitivity, of heat-elicited TRPV1 cur-
rents [22]. This is also supported by our ﬁnding that the
initial current densities were equal between cells treated
with MβCD:cholesterol and control cells in measure-
ments of TRPV1 with 1 μM capsaicin as agonist and
NMDG as the sole extracellular cation (Figure 2A). More-
over, whole-cell patch-clamp measurements, using pro-
tons (pH 5.5) for activation of TRPV1, indicated that the
amount of functional ion channels in the cell membrane
was unaﬀected by theMβCD:cholesterol treatment. Here,
the initial current densities remained unchanged, and only
the second current densities (arising from pore dilation)
were inhibited by treatment upon activation with pH 5.5
(Figure 3A–B). Hence, as initial current densities were
similar for both activation with pH 5.5 and 1 μM cap-
saicin, together with the observation of similar heat-
elicited uptake rates of YO-PRO and current densities in
treated and control cells, we suggest that the cholesterol
depletion did not aﬀect the number of functional channels
in the plasma membrane. Furthermore, we also suggest
that an eﬀect of cholesterol depletion under hypocalcemic
conditions is only observed in TRPV1 current responses
associated with an ionic selectivity change of TRPV1.
Another previous study showed that modulation of
cholesterol content inhibited TRPV1 function through
binding to speciﬁc sites along the S5 helix of the ion chan-
nel which include a cholesterol recognition/interaction
amino acid consensus [20]. However, none of the men-
tioned studies connect modulation of cellular cholesterol
content with the dynamic ionic selectivity which can be
induced during prolonged exposure of TRPV1 to an ago-
nist. Thus, our ﬁndings suggest that cellular cholesterol
depletion interferes with the time-dependent increase
of the relative cation permeability of TRPV1 [12], found
during sustained activation with capsaicin or protons.
This may inhibit the ability of TRPV1 channels to
mediate changes of potentials across the membranes of
nociceptors.
Conclusions
We have demonstrated a novel mechanism whereby a
decrease of the cholesterol content of a cell aﬀects the
ionic selectivity of TRPV1. Prolonged agonist-mediated
activation of TRPV1 channels in cells under hypocalcemic
conditions may constitute a mechanism which facilitates
nociception and neurogenic inﬂammation, and our results
indicate that cholesterol depletion can inhibit these pro-
cesses. Our data further supports previous investigations,
suggesting that cholesterol depletion of the cell modulates
the TRPV1 ion channel, which, in turn, may ameliorate
pain and inﬂammation.
Methods
Cell culture
Adherent Chinese hamster ovary (CHO) cells with a tetra-
cycline regulated expression system (T-REx) for inducible
expression of human TRPV1 were a kind gift from Astra
Zeneca, R&D, CNS & Pain, So¨derta¨lje, Sweden, and were
cultured in T25-ﬂasks and Petri dishes for 2–6 days in
medium (DMEM or DMEM/Ham’s F12 with glutamine)
supplemented with 10% fetal calf serum, zeocin (350
μg/ml) and blasticidin (5 μg/ml). 18–24 hours prior to
experiments, the cells were incubated in medium sup-
plemented with 10% fetal calf serum and doxycycline
(1 μg/ml) in order to induce expression of the TRPV1
protein.
Cholesterol depletion treatment
The 2.5 mM MβCD:cholesterol (10:1) solution was pre-
pared with the direct addition of cholesterol and MβCD
in the appropriate molar ratio, into serum-free medium.
The solution was incubated over night at 37◦C on a rotary
shaker, and was ﬁltered through a 0.45 μm ﬁlter before
use. The 10 mM MβCD solution was prepared by imme-
diate dissolution of MβCD into an appropriate volume
of serum-free medium. Prior to experiments, cells were
washed with serum-free solution followed by an incuba-
tion period with either 15 min of 10 mMMβCD or 90min
of 2.5 mMMβCD:cholesterol (10:1).
Gas-chromatographic analysis
Cells treated with either 10 mM MβCD or 2.5 mM
MβCD:cholesterol (10:1), and control cells only cultured
in medium, were detached with Accutase and pelleted.
The supernatant was discarded, the cell pellet was there-
after washed with phosphate-buﬀered saline (PBS) and
centrifuged (5 min, 600×g) twice. Before the ﬁnal cen-
trifugation step, an aliquot was collected for cell count-
ing, which was performed with a Bu¨rker hemocytometer.
Cholesterol was extracted from cell pellets by incuba-
tion with a hexane/isopropanol (3:2) solution for 4 h.
A solution of 5α-cholestane in chloroform (50 μl, 0.5
mg/ml) was added to all samples as internal standard,
thereafter samples were dried with nitrogen. Before gas-
chromatographic measurements, the dry samples were
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dissolved in 50 μl Sylon HTS and incubated for 30 min
at 65◦C, whereafter 50 μl of chloroform was added.
Cholesterol content of cells without saponiﬁcation was
determined using an HP 5950/5972 gas-chromatography
mass-spectrometer (GC–MS) [23-26]. One microlitre
(1 μl) of the analyte was injected for analysis, and was
separated on an RTX-20 column (Restek, U.S.A.). The
inlet temperature was set to 250◦C, helium was used as
carrier gas, the oven was on hold for 5 min at 250◦C,
then ramped 5◦C/min to 260◦C were it remained on
hold, and the detector was hold at 300◦C. Total ion
mass spectra were recorded in a mass over charge (m/z)
range of 50–550, total time for GC–MS detection was
20 min.
Chemicals
Cell culturing medium (DMEM and DMEM/Ham’s F12
with glutamine), fetal bovine serum, and Accutase were
purchased from PAA, Pasching, Austria; Zeocin and YO-
PRO-1 were purchased from Invitrogen. All other chem-
icals were purchased from Sigma. Buﬀers contained (in
mM): 1, 150 NaOH, 5 EGTA, 10 HEPES; pH adjusted to
7.4 with HCl. 2, 150 NMDG, 10 EGTA, 10 HEPES; pH
adjusted to 7.4 with HCl. 3, 150 NaOH, 1MgCl2, 5 EGTA,
10 HEPES; pH adjusted to 7.4 with HCl. 4, 140 NaCl, 5
KCl, 1 MgCl2, 10 HEPES, 10 D-glucose, 10 Na4BAPTA;
pH adjusted to 5.5 with HCl. 5, 120 KCl, 2 MgCl2, 10
Na4BAPTA, and 10 HEPES; pH adjusted to 7.2 with KOH.
6, 140 NaCl, 5 KCl, 1 CaCl2, 1 MgCl2, 10 Hepes, 10 D-
glucose; pH adjusted to 7.4 with NaOH. 7, 120 KCl, 1
CaCl2, 2 MgCl2, 11 EGTA, and 10 HEPES; pH adjusted to
7.2 with KOH. 8, 140 NaCl, 5 KCl, 1 MgCl2, 10 HEPES, 10
D-glucose, 10 Na4BAPTA; pH adjusted to 7.4 with NaOH.
PBS, 136 NaCl, 2.7 KCl, 10 NA2HPO4, 1.8 KH2PO4; pH
adjusted to 7.4 with NaOH.
Electrophysiology
All electrophysiological experiments were performed
using a microﬂuidic device for patch-clamp (Dynaﬂow,
Cellectricon AB, Go¨teborg, Sweden). Data was recorded
using a HEKA EPC10 patch-clamp ampliﬁer with Patch-
master software (HEKA Elektronik, Germany). Pipettes
were pulled from borosilicate capillaries (GC-150F,
Harvard Apparatus, U.K.) with a resistance of 1–12 MΩ.
Cells were clamped at −60 mV and series resistance
compensation was performed up to 80%. Voltage ramp
protocols were executed with a rate of 1 Hz, with −60
mV as resting potential and ranged from −120 mV to
+30 mV over 150 ms. Whole-cell patch-clamp record-
ings were sampled at 5 kHz and low pass ﬁltered at 1
kHz. Data was analyzed with Fitmaster (HEKAElektronik,
Germany) and Matlab (Mathworks, MA, U.S.A.).
The relative permeability PNMDG/PNa can be derived
from the Goldman–Hodgkin–Katz equation, and is calcu-
lated as
PNMDG
PNa
= [ NMDG
+]o
[ Na+]o
exp ErevFRT (1)
where F is the Faraday constant, R is the gas con-
stant, Erev is the diﬀerence in Erev between extracellular
NMDG+ and Na+ measured in parallel cells, T is the tem-
perature, and [ NMDG+]o and [ Na+]o are the activities of
extracellular NMDG+ and Na+, respectively.
Temperature control
For electrophysiological experiments, resistive heating
coils (2 nm of Cr followed by a 10 nm transparent Au
ﬁlm) were evaporated onto the glass underside of the
Dynaﬂow chip, as previously described [29,30]. Heating
was achieved with a current limiting standard power sup-
ply with an accuracy of ±0.2◦C. Cooling was achieved by
simple heat dissipation after turning oﬀ the heating stage.
The temperature in the ﬂow close to the patch-clamped
cell was measured using a calibrated micron-sized Cu/Ni
thermoelement (Omega Ltd., U.K.).
For ﬂuorescence measurements, heating of cells was
achieved with a 5W 1470 nm (IR-B) semiconductor diode
laser (Seminex HHF-1470-6-95, Seminex, Peabody, MA,
U.S.A.) used in conjunction with a 50 μm core diameter,
0.22NA optical ﬁber (OceanOptics, Dunedin, FL, U.S.A.),
and the temperature close to the cells was determined
using a thermoelement, as described above.
YO-PRO uptake assay
YO-PRO uptake was measured with ﬂuorescence using
a Leica IRE2 confocal microscope equipped with a Leica
TCS SP confocal scanner, an oil-immersion 40× NA
1.3 Leica HCX PL APO CS objective, and Leica con-
focal software (Leica Microsystems GmbH, Germany).
Fluorescence was measured from single cells, with exci-
tation at 488 nm and emission at either 505-600 nm or
555–625 nm, images collected at a rate of 0.3–0.6 Hz.
Stimulation of cells with agonists together with 1 μMYO-
PRO was performed using either a microﬂuidic pipette
(Avalance Biotech AB, Go¨teborg, Sweden), providing per-
fusion within a conﬁned volume in the cell dish [27,28],
or with a microﬂuidic device providing rapid well per-
fusion (Auto-GP, Cellectricon AB, Go¨teborg, Sweden).
Brieﬂy before the onset of agonist, cells were perfused
with YO-PRO in the absence of agonist to assure the cell
membranes to be intact. Data was analyzed with Leica
confocal software and Matlab (Mathworks, MA, U.S.A.).
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Statistical analysis
All statistical analysis was performed with Student’s
paired or unpaired t-test where applicable. Results were
considered statistically signiﬁcant if p < 0.05, and indi-
cated with an asterisk (*) in Figures where applicable. Data
is presented as mean plus/minus one standard deviation.
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